Oğuzhan DOĞANLAR, Zeynep Banu DOĞANLAR, Ayten DOĞAN

Combined treatment of cisplatin and 5-Fluorouracil Induces cell death in ARPE-19 cells through the endoplasmic reticulum stress pathway

Aim: Cisplatin and 5-Fluorouracil have been used for about 50 years as chemotherapy agents. Combination of these two agents is known as PF therapy and is widely used in the treatment of anal, esophageal cancer, head and neck cancer. One of the problems encountered with antineoplastic agents is the rapid and irreversible side effects on non-target cells and organs. It is common that occourence of ocular toxicity by chemotherapy. Materials and Methods: ARPE-19 cell viability and toxicity were determined by performing (MTT)-based colorimetric assays and IC50 values calculated by probit analyses options of SPSS 20 Software. Acridine orange/Ethidium bromide (AO/EB) fluorescent staining was performed to determine structural changes such as cell blebbing and chromatin condensation during the apoptosis process on cells. Images examined under a fluorescent microscope (Zeiss Axio Vert.A1) at 40X magnification with FITC filter for AO and Tex Red filter. And Real-time PCR was performed with ABI Step One Plus and Quant Studio 5 Real-Time PCR systems.Results: PF treatment within 24 hours and 48 hours caused ER stress due to toxic effect and this induced cell death through apoptosis via death receptor signaling and intrinsic pathway in ARPE-19 cells. Conclusion: PF-induced activation of the ER stress mechanism can be used as a novel therapeutic strategy for the prevention of side effects of non-target cells.

PDF

___

1. Kovács R, Csenki Z, Bakos K, et al. Assessment of toxicity and genotoxicity of low doses of 5-fluorouracil in zebrafish (Danio rerio) two-generation study. Water Res 2015;77:201-12.
2. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78.
3. Guclu H, Doganlar ZB, Gurlu VP, et al. Effects of cisplatin- 5-fluorouracil combination therapy on oxidative stress, DNA damage, mitochondrial apoptosis, and death receptor signalling in retinal pigment epithelium cells. Cutan Ocul Toxicol 2018;37:291-304.
4. Al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy: a review. Cancer 1996;78:1359-73.
5. Hazin R, Abuzetun JY, Daoud YJ, et al. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol 2009;20:308-17.
6. Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer 1981;48:1539-49.
7. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845-81.
8. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007;10:103.
9. Penha FM, Rodrigues EB, Maia M, et al. Retinal and ocular toxicity in ocular application of drugs and chemicals–part II: retinal toxicity of current and new drugs. Ophthalmic Res 2010;44:205-24.
10. Yoshikawa T, Ogata N, Izuta H, et al. Increased expression of tight junctions in ARPE-19 cells under endoplasmic reticulum stress. Curr Eye Res 2011;36:1153-63.
11. Zode GS, Sharma AB, Lin X, et al. Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma. J Clin Invest 2014;124:1956-65.
12. Mandic A, Hansson J, Linder S, et al. Cisplatin induces endoplasmic reticulum stress and nucleusindependent apoptotic signaling. J Biol Chem 2003;278:9100-6.
13. Becher R, Schütt P, Osieka R, et al. Peripheral neuropathy and ophthalmologic toxicity after treatment with cisdichlorodiaminoplatinum II. J Cancer Res Clin Oncol 1980;96:219-21.
14. Berman I, Mann M. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 1980;45:764-6.
15. Caruso R, Wilding G, Ballintine E, et al. Cisplatin retinopathy. Invest Ophthalmol Vis Sci 1985;26:34.
16. Cohen RJ, Cuneo RA, Cruciger MP, et al. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. J Clin Oncol 1983;1:392-3.
17. Diamond SB, Rudolph SH, Lubicz SS, et al. Cerebral blindness in association with cis-platinum chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol 1982;59:6-84.
18. Pippitt Jr CH, Muss HB, Homesley HD, et al. Cisplatinassociated cortical blindness. Gynecol Oncol 1981;12:253-5.
19. Zhang N, Yin Y, Xu S-J, et al. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008;13:1551-69.
20. Shah MY, Pan X, Fix LN, et al. 5-fluorouracil drug alters the microrna expression profiles in MCF-7 breast cancer cells. J Cell Physiol 2011;226:1868-78.
21. Kunz C, Focke F, Saito Y, et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 2009;7:e1000091.
22. De Angelis PM, Svendsrud DH, Kravik KL, et al. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 2006;5:20.
23. Abraham LM, Selva D, Casson R, et al. The clinical applications of fluorouracil in ophthalmic practice. Drugs 2007;67:237-55.
24. Hotnog D, Mihãilã M, Lancu I, et al. Resveratrol modulates apoptosis in 5-fluorouracyl treated colon cancer cell lines. Roum Arch Microbiol Immunol 2013;72:255-64.
25. Hamersley J, Luce JK, Florentz TR, et al. Excessive lacrimation from fluorouracil treatment. JAMA Netw 1973;225:747-8.
26. Straus DJ, Mausolf FA, Ellerby RA, et al. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977;3:15-9.
27. Christophidis N, Vajda F, Lucas I, et al. Ocular side effects with 5-fluorouracil. Aust N Z J Med 1979;9:143- 4.
28. Horio T, Murai T, Ikai K. Photosensitivity due to a fluorouracil derivative. Arch Dermatol 1978;114:1498- 500.
29. Foufelle F, Fromenty B. Role of endoplasmic reticulum stress in drug-induced toxicity. Pharmacol Res Perspect 2016;4.
30. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008;123:1227-39.
31. Lu TH, Su CC, Chen YW, et al. Arsenic induces pancreatic beta-cell apoptosis via the oxidative stress-regulated mitochondria-dependent and endoplasmic reticulum stress-triggered signaling pathways. Toxicol Lett 2011;201:15-26.
32. Van Hennik MB, van der Vijgh WJ, Klein I, et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Research 1987;47:6297-301.
33. Andreadis C, Vahtsevanos K, Sidiras T, et al. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncology 2003;39:380-5.
34. Focaccetti C, Bruno A, Magnani E, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PloS one 2015;10:e0115686.
35. Ribble D, Goldstein NB, Norris DA, et al. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotech 2005;5:12.
36. Ye Y, Shibata Y, Yun C, et al. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004;429:841.
37. Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Update 2004;7:345-58.
38. Ko LJ, Prives C. p53: puzzle and paradigm. Gene Dev 1996;10:1054-72.
39. Shibue T, Suzuki S, Okamoto H, et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J 2006;25:4952-62.
40. Erlacher M, Michalak EM, Kelly PN, et al. BH3- only proteins Puma and Bim are rate-limiting for γ-radiation–and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005;106:4131-8.